Software for analysis and reporting of single cell data will advance research into cell function, disease progression, and therapeutic response
This Smart News Release features multimedia. View the full release here:http://www.businesswire.com/news/home/20160810005216/en/
“We are excited to partner with
“FlowJo, LLC is recognized for delivering reliable, high-quality and easy-to-use software solutions that allow cell biologists to study phenotype in individual cells by flow cytometry,” said
The software will complement the end-to-end commercial solution for high-throughput sequencing of single cells that
The companies expect the software to be available in Q1 2017.
About
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and follow @illumina.
About
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, such as Illumina’s expectations regarding the launch of any products. Important factors that could cause actual results to differ materially from those in forward-looking statements include the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, and the other factors detailed in Illumina’s filings with the
View source version on businesswire.com: http://www.businesswire.com/news/home/20160810005216/en/
Source:
Illumina, Inc.
Investors:
Rebecca Chambers
858-255-5243
ir@illumina.com
or
Media:
Gwen Gordon
858-882-6822
pr@illumina.com
or
FlowJo, LLC
Media:
Caitlin Farquhar
800-366-6045
caitlinf@flowjo.com